
A clinical trial involving 1362 female breast cancer patients investigated neoadjuvant fulvestrant or A+F's impact on endocrine-sensitive disease compared to anastrozole alone. Results showed no significant improvement in 6-month endocrine-sensitive disease rates (ESDR) with fulvestrant or A+F. Neither regimen enhanced week 4 Ki67 suppression compared to anastrozole. Luminal B tumors responded better to A+F regarding week 4 Ki67 suppression. In conclusion, neither fulvestrant nor A+F demonstrated a notable advantage over anastrozole, affirming aromatase inhibition as the standard of care for ER-rich/ERBB2-negative breast cancer.
Like
Save
Share